Parkinson s s disease: diagnosis and long-term management

Size: px
Start display at page:

Download "Parkinson s s disease: diagnosis and long-term management"

Transcription

1 Parkinson s s disease: diagnosis and long-term management Dr Richard Grunewald Consultant Neurologist Sheffield Teaching Hospitals NHS Trust

2 How do we move? We need constantly to process a vast amount of joint position afferent information from muscle spindles QuickTime and a TIFF (Uncompressed) decompressor are needed to see this picture. QuickTime and a TIFF (Uncompressed) decompressor are needed to see this picture.

3 What are the basal ganglia doing? processing all that afferent information This allows us to stay upright, predict where our limbs will be just ahead of movement, adjust for fatigue and load. Disorders of the basal ganglia involve failure of this (i.e. movement disorders) QuickTime and a TIFF (Uncompressed) decompressor are needed to see this picture.

4 What is PD anyway? Neurodegenerative disease fairly specific for dopaminergic neurones in the brain.but there are several other things that look rather similar!

5 Vascular Parkinsonism/NPH Brain is unique in being enclosed in a rigid container You can t get blood in unless something comes out at the same time QuickTime and a TIFF (Uncompressed) decompressor are needed to see this picture.

6 Vascular Parkinsonism/NPH Gait apraxia is common in the elderly Lower half parkinsonism is the more severe end of the spectrum Ubiquitous in the elderly Blood supply to the brain is difficult as the brain is enclosed in a rigid box (the skull) Mismatch of blood flow into the skull with venous drainage during the cardiac cycle is usually compensated by flow of CSF in and out of the skull Failure of bi-directional CSF flow down the acqueduct occurs as we get older, as blood supply to the brain becomes more pulsatile (atherosclerosis) Global brain ischaemia results - effects basal ganglia early Ventriculoperitoneal shunt helps some (normal pressure hydrocephalus QuickTime and a TIFF (Uncompressed) decompressor are needed to see this picture.

7 Idiopathic Parkinson s s disease Neurodegenerative condition associated with loss of dopaminergic neurones Cause(s) obscure, but a very small number of cases inherited QuickTime and a TIFF (Uncompressed) decompressor are needed to see this picture.

8 Progression of IPD Predictable At first one or two doses of l-dopa sufficient to control symptoms throughout the day Then early wearing off peak dose dyskinesia On-off fluctuations Drug-induced psychosis Dementia

9 Progression of IPD Early wearing off Patients notice effect of drug wanes before next dose is due Increase frequency of dosing Try controlled release medication

10 Progression of IPD Peak dose dyskinesia Involuntary fidgeting movements when l-dopa in bloodstream is at peak level Manage by using direct-acting dopaminergic agonist drugs

11 Progression of IPD On-off fluctuations Progression of predictable end-of-dose wearing off of l-dopa to increasingly random fluctuation between off state (immobile) and on state with or without dyskinesia Management as for peak dose dyskinesia

12 Progression of IPD Drug-induced psychosis Starts with illusions Hallucinations (mainly visual) in the evening Delusions (spouse infidelity) Paranoia Try to reduce dopaminergic agonist Cautious use of atypical neuroleptics Dementia

13 Progression of IPD Hypersexuality Compulsive ideation Gambling others

14 Complications of PD Result of two processes: Presynaptic neurone loss Postsynaptic receptor supersensitivity QuickTime and a TIFF (Uncompressed) decompressor are needed to see this picture.

15 Other problems Sleep - multifactorial Mood Salivation - botulinum toxin injections Pain Twitching

16 Complications of PD Early wearing off caused by reducing storage capacity for dopamine On-off fluctuations, dyskinesia and psychosis caused by postsynaptic changes QuickTime and a TIFF (Uncompressed) decompressor are needed to see this picture.

17 What else is going wrong in Parkinson s s disease? Pathology extends outside basal ganglia Dementia, autonomic instability QuickTime and a TIFF (Uncompressed) decompressor are needed to see this picture. QuickTime and a TIFF (Uncompressed) decompressor are needed to see this picture.

18 What else is going wrong in Parkinson s s disease? Increasing sensitivity to the side effects of the drugs Increasingly difficult balance between symptom control and adverse effects QuickTime and a TIFF (Uncompressed) decompressor are needed to see this picture.

19 I have a patient who I think has PD. Do I start treatment straight away or refer, and if so to whom? Referral is recommended fo r confirmation of diagnosis, planning managemen t, counselling and edu cation and initiation of therapy. Younge r patients shou ld be referred to the Mo vement Disorder Clinic, Department of Neu rology, the Ro yal Hallamshire Hospital, telephone , fax Older patients with more complex co-morbidity and rehabilitation needs to Dr J Liddle, Department of Hea lthcare of the Elderly, Brearley Wing, Northern General Hospital, fax , te lephone or Dr N Samaniego, Department of HealthCare of the Elderly, Royal Hallamshire Hospital, fax , te lephone or

20 Do I start treatment? NICE recommends prompt referral for assessment (but this is not funded) No evidence for adverse effect of early treatment Treatment can mask symptoms making expert assessment problematic Expert follow up essential Patient and family need support

21 But I ve I heard L-dopa L is toxic and we should avoid using it until we have to. QuickTime and a TIFF (Uncompressed) decompressor are needed to see this picture. it isn t!

22 My patient has come back from Dr Grunewald s clinic telling me she has been started on a drug called pramipexole and is asking for a repeat prescription. I have never heard of this drug. Why is he asking me to prescribe this? Shouldn t t the dose be adjusted by his team, not me? Pramipexole is one of the range of dopaminergic agonist drugs Safe as any Titration takes many months and as the disease progresses further adjustment necessary How to provide backup and continuity? With 500 patients with PD alone on our books we can t see everyone even every year. Our nurses can!

23 Quick guide to dopaminergic agonist drugs: Continuous dopaminergic stimulation? improves prognosis Effective in reducing on-off swings, dyskinesia if dose maximised and l-dopa minimised Bromocriptine original and best, but you need to use enough Cabergoline less potent, long half life (3days) Ropinirole non ergot drug, less potent, makes patients sleepy Pramipexole like Ropinirole but more potent and more sleepy Rotigotine like ropinirole but in a patch

24 Magic recipe for PD Treats 90% of patients optimally L-dopa plus peripheral decarboxylase inhibitor five times daily (e.g. co-beneldopa, co-careldopa 125) Full dose direct acting agonist five times daily (e.g. bromocriptine 20mg, pramipexole 0.7mg, ropinirole 5mg)

25 My patient did not seem to respond to l- dopa or the other more expensive drugs and is getting increasingly immobile. What do I do? Is the diagnosis sound? Consider vascular parkinsonism Normal pressure hydrocephalus Parkinson s plus syndromes Cervical myelopathy Refer for Consultant opinion In Sheffield younger patients to Royal Hallamshire (Neurology) Those with complex problems benefit from MDT assessment at ARC or Northern General

26 What is apomorphine? Produced from morphine, but chemically unrelated Given parenterally (subcutaneous) Boluses for unpredictable offs Continuous infusion for refractory psychosis or fluctuations Very irritant Also used to stimulate libido Expensive ( 10,000 per annum) QuickTime and a TIFF (Uncompressed) decompressor are needed to see this picture. QuickTime and a TIFF (Uncompressed) decompressor are needed to see this picture.

27 What is Duodopa? Duodenal dopa infusion gel Continuous infusion 30,000 per annum Little evidence on effectiveness QuickTime and a TIFF (Uncompressed) decompressor are needed to see this picture. QuickTime and a TIFF (Uncompressed) decompressor are needed to see this picture.

28 My patient has come to me with a cutting from the Daily Mirror saying that Stalevo is a wonder drug. Should she be taking it? Mixture of l-dopa, peripheral dopa decarboxylase inhibitor and entacapone Increases delivery of l-dopa to the brain (but so does an increased dose of l-dopa, cheaper) No particular advantage in most patients.

29 My patient has come to me with a cutting from the Daily Mirror saying that Rasagaline is a wonder drug. Should she be taking it? Me too version of selegeline In clinical trials as effective as selegeline (!) No particular advantage in most patients. Why use selegeline anyway? Small symptomatic effect Well tolerated Antidepressant No prognostic advantage demonstrated

30 My patient has come to me with a cutting from the Daily Mirror saying that Rotigotine is a wonder drug. Should she be having it? Dopamine agonist patch In clinical trials more effective than placebo (!) Not very potent Advantage that you can stop treatment quickly, and that patient does not need to swallow tablets? Less likely to precipitate hallucinations

31 My patient with PD is getting increasingly difficult at home - paranoid and sexually demanding. What should I do? Dopaminergic drugs stimulate libido Hallucinations and delusions are common druginduced complications of advanced PD Reduce dopaminergic drugs Direct acting agonists first Antidepressants, amantidine, selegeline L-dopa Refer to specialist service or if things are nearing crisis direct to on-call team.

32 My patient with PD has recently been started on clozapine.. I know this is a dangerous drug. Why is this and what do I have to do to monitor him? Clozapine has a unique place in management of drug-induced psychosis Patients are registered with the Clozaril patient monitoring service You arrange to have the blood taken, we do the rest.

33 My patient with PD has recently been started on a drug called tolcapone.. I know there is a perfectly good drug in this class called entacapone.. The patient now needs regular blood tests. Why? Tolcapone is a COMT inhibitor, like entacapone Tolcapone is much more effective in reducing on-off swings and dyskinesia 1 in 20,000 patients have liver failure on the drug..

34 My patient is not satisfied with the opinion on his condition - he has heard there is a scan which makes the diagnosis. Can he have it? DAT scans distinguish between groups of patients with essential tremor and those with IPD. So does l-dopa challenge! 750

35 My patient has asked me about surgery for his PD - he has heard that people are having treatment with stem cells, infusions of growth factors, radiosurgery and lasers. Can he have these too? DBS for PD available in Sheffield Surgical treatment for other movement disorders also available here For stem cells, growth factors needs another planet.

36 I am quite interested in PD but also have a day job. Is there a quick and easy source of information for me to help me with common PD associated problems? PD nurses have an invaluable role in providing continuity of care, advice and cost-effective timely intervention Multidisciplinary teams including physio, OT, speech therapy required to optimise care Open access to specialist Consultant advice

37 Why do we need a shared care protocol? Inform about the disorder and its treatments Define standard of care, e.g. what the patient can expect of us Document the services available Define who does what Prevent disputes!

38 Conclusions Parkinsonism is a complex group of degenerative conditions Multi-disciplinary input required to get the best out of the patient Effective, quick crisis management required Communication, communication, communication.

10th Medicine Review Course st July Prakash Kumar

10th Medicine Review Course st July Prakash Kumar 10th Medicine Review Course 2018 21 st July 2018 Drug Therapy for Parkinson's disease Prakash Kumar National Neuroscience Institute Singapore General Hospital Sengkang General Hospital Singhealth Duke-NUS

More information

PARKINSON S MEDICATION

PARKINSON S MEDICATION PARKINSON S MEDICATION History 1940 50 s Neurosurgeons operated on basal ganglia. Improved symptoms. 12% mortality 1960 s: Researchers identified low levels of dopamine caused Parkinson s leading to development

More information

Treatment of Parkinson s Disease: Present and Future

Treatment of Parkinson s Disease: Present and Future Treatment of Parkinson s Disease: Present and Future Karen Blindauer, MD Professor of Neurology Director of Movement Disorders Program Medical College of Wisconsin Neuropathology: Loss of Dopamine- Producing

More information

Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE

Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE LEARNING OBJECTIVES The Course Participant will: 1. Be familiar with the pathogenesis of Parkinson s Disease (PD) 2. Understand clinical

More information

Parkinson s Disease. Gillian Sare

Parkinson s Disease. Gillian Sare Parkinson s Disease Gillian Sare Outline Reminder about PD Parkinson s disease in the inpatient Surgical patients with PD Patients who cannot swallow End of life care Parkinson s disease PD is the second

More information

Let s Look at Parkinson s (PD) Sheena Morgan Parkinson s Disease Nurse Specialist Isle of Wight NHS Trust November 2016

Let s Look at Parkinson s (PD) Sheena Morgan Parkinson s Disease Nurse Specialist Isle of Wight NHS Trust November 2016 Let s Look at Parkinson s (PD) Sheena Morgan Parkinson s Disease Nurse Specialist Isle of Wight NHS Trust November 2016 What is Parkinson s? Parkinson's is a progressive neurological condition. People

More information

Optimizing Clinical Communication in Parkinson s Disease:

Optimizing Clinical Communication in Parkinson s Disease: Optimizing Clinical Communication in Parkinson s Disease:,Strategies for improving communication between you and your neurologist PFNCA Symposium March 25, 2017 Pritha Ghosh, MD Assistant Professor of

More information

Parkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai

Parkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai Parkinson s disease Therapeutic strategies Surat Tanprawate, MD Division of Neurology University of Chiang Mai 1 Scope Modality of treatment Pathophysiology of PD and dopamine metabolism Drugs Are there

More information

Commonly encountered medications and their side effects - what the generalist needs to know

Commonly encountered medications and their side effects - what the generalist needs to know Commonly encountered medications and their side effects - what the generalist needs to know Jeremy Cosgrove Consultant Neurologist Leeds Teaching Hospitals NHS Trust Outline: Parkinson s medications and

More information

Communicating About OFF Episodes With Your Doctor

Communicating About OFF Episodes With Your Doctor Communicating About OFF Episodes With Your Doctor Early in Parkinson s disease (PD), treatment with levodopa and other anti-pd drugs provides continuous benefit. As the disease progresses, however, symptom

More information

Dr Barry Snow. Neurologist Auckland District Health Board

Dr Barry Snow. Neurologist Auckland District Health Board Dr Barry Snow Neurologist Auckland District Health Board Dystonia and Parkinson s disease Barry Snow Gowers 1888: Tetanoid chorea Dystonia a movement disorder characterized by sustained or intermittent

More information

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Overview n Brief review of Parkinson s disease (PD) n Clinical manifestations n Pathophysiology

More information

Parkinson's Disease and how you can make a difference with medication

Parkinson's Disease and how you can make a difference with medication Parkinson's Disease and how you can make a difference with medication Alyson Franks Parkinson's and Movement Disorder Nurse Specialist Royal Hallamshire Hospital No treatment all Complementary Therapy

More information

Parkinson s disease. Information for patients and carers. The Leeds Teaching Hospitals NHS Trust

Parkinson s disease. Information for patients and carers. The Leeds Teaching Hospitals NHS Trust n The Leeds Teaching Hospitals NHS Trust Parkinson s disease Information for patients and carers in partnership with Leeds Community Healthcare NHS Trust The symptoms of Parkinson s appear when the levels

More information

The Shaking Palsy of 1817

The Shaking Palsy of 1817 The Shaking Palsy of 1817 A Treatment Update on Parkinson s Disease Dr Eitzaz Sadiq Neurologist CH Baragwanath Acadamic Hospital Parkinson s Disease O Premature death of dopaminergic neurons O Symptoms

More information

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology + Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Associate Professor of Neurology + Disclosures n NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT + Learning

More information

Re-Submission. Scottish Medicines Consortium. rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd.

Re-Submission. Scottish Medicines Consortium. rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd. Scottish Medicines Consortium Re-Submission rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd 10 November 2006 The Scottish Medicines Consortium (SMC) has completed

More information

Best Medical Treatments for Parkinson s disease

Best Medical Treatments for Parkinson s disease Best Medical Treatments for Parkinson s disease Bernadette Schöneburg, M.D. June 20 th, 2015 What is Parkinson s Disease (PD)? Progressive neurologic disorder that results from the loss of specific cells

More information

ACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM

ACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM ACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM 1 CONTENTS: TOPIC PAGE Introduction 3 What should you do when a PD

More information

Medications used to treat Parkinson s disease

Medications used to treat Parkinson s disease Medications used to treat Parkinson s disease Edwin B. George, M.D., Ph.D. Director of Wayne State University Movement Disorder Clinic University Health Center Neurology Clinic University Health The John

More information

Parkinson's Disease KP Update

Parkinson's Disease KP Update Parkinson's Disease KP Update Andrew Imbus, PA-C Neurology, Movement Disorders Kaiser Permanente, Los Angeles Medical Center No disclosures "I often say now I don't have any choice whether or not I have

More information

Key Concepts and Issues in Parkinson s Disease in 2016

Key Concepts and Issues in Parkinson s Disease in 2016 Key Concepts and Issues in Parkinson s Disease in 2016 Michael Rezak, M.D., Ph.D. Section Chief, Neurosciences Institute Director, Movement Disorders and Neurodegenerative Diseases Center Northwestern

More information

PARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease

PARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease 5/11/16 PARKINSON S DISEASE Parkinson s disease Prevalence increases with age (starts 40s60s) Seen in all ethnic groups, M:F about 1.5:1 Second most common neurodegenerative disease Genetics role greater

More information

Parkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee

Parkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee Parkinson Disease Lorraine Kalia, MD, PhD, FRCPC Key Learnings Parkinson Disease (L. Kalia) Key Learnings Parkinson disease is the most common but not the only cause of parkinsonism Parkinson disease is

More information

Pa t h w a y s. Pa r k i n s o n s. MacMahon D.G. Thomas S. Fletcher P. Lee M. 2006

Pa t h w a y s. Pa r k i n s o n s. MacMahon D.G. Thomas S. Fletcher P. Lee M. 2006 Pathways bolt 16/6/06 20:38 Page 1 Pa t h w a y s A PARADIGM FOR DISEASE MANAGEMENT IN Pa r k i n s o n s Disease MacMahon D.G. Thomas S. Fletcher P. Lee M. 2006 Clinical diagnosis Pa r k i n s o n s disease

More information

Parkinson s disease: diagnosis and current management

Parkinson s disease: diagnosis and current management n DRUG REVIEW Parkinson s disease: diagnosis and current management Lucy Collins MPhil, Gemma Cummins MRCPI and Roger A Barker PhD, MRCP SPL Treatment for Parkinson s should be tailored to the needs of

More information

Clinical Guideline for the management of inpatients with Parkinson s disease

Clinical Guideline for the management of inpatients with Parkinson s disease Clinical Guideline for the management of inpatients with Parkinson s disease Introduction: Parkinson s disease (PD) is the second most common neurodegenerative disorder, characterised by bradykinesia,

More information

Program Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York

Program Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York Program Highlights David Swope, MD Associate Professor of Neurology Mount Sinai Health System New York, New York Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone

More information

New Medicines Committee Briefing July 2011

New Medicines Committee Briefing July 2011 New Medicines Committee Briefing July 2011 Pramipexole immediate-release (Mirapexin ) and Pramipexole modifiedrelease (Mirapexin prolonged release) for the treatment of Parkinson s Disease Pramipexole

More information

Evaluation and Management of Parkinson s Disease in the Older Patient

Evaluation and Management of Parkinson s Disease in the Older Patient Evaluation and Management of Parkinson s Disease in the Older Patient David A. Hinkle, MD, PhD Comprehensive Movement Disorders Clinic Pittsburgh Institute for Neurodegenerative Diseases University of

More information

Issues for Patient Discussion

Issues for Patient Discussion onmotor complications radykinesia Screening Tools asked PD micrographia eurodegeneration Designed for Use by Family Practitioners remor on-off opamine agonists tiffness depression ostural instability wearing

More information

Appendix N: Research recommendations

Appendix N: Research recommendations Appendix N: recommendations N.1 First-line treatment of motor symptoms recommendation 1 Interventions What is the effectiveness of initial levodopa monotherapy versus initial levodopa-dopamine agonist

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium rotigotine 2mg/24 hours, 4mg/24 hours, 6mg/24 hours, 8mg/24 hours transdermal patch (Neupro ) (No: 289/06) Schwarz Pharma Ltd. 7 July 2006 The Scottish Medicines Consortium

More information

Objectives. Emerging Treatments in Parkinson s s Disease. Pathology. As Parkinson s progresses it eventually affects large portions of the brain.

Objectives. Emerging Treatments in Parkinson s s Disease. Pathology. As Parkinson s progresses it eventually affects large portions of the brain. Objectives Emerging Treatments in Parkinson s s Disease 1) Describe recent developments in the therapies for Parkinson s Disease Jeff Kraakevik MD Assistant Professor OHSU/Portland VAMC Parkinson s Center

More information

Parkinson s disease. Quick reference guide. Issue date: June Diagnosis and management in primary and secondary care

Parkinson s disease. Quick reference guide. Issue date: June Diagnosis and management in primary and secondary care Quick reference guide Issue date: June 2006 Parkinson s disease Diagnosis and management in primary and secondary care Developed by the National Collaborating Centre for Chronic Conditions Contents Contents

More information

Acute management of in-patient Parkinson s Disease patients

Acute management of in-patient Parkinson s Disease patients Acute management of in-patient Parkinson s Disease patients Contents Pages Introduction and Admission advice 2 Nil by Mouth Guidance 3 5 Complex therapy advice (Apomorphine, DBS, Duodopa) 6 Surgical peri-operative

More information

Novel approaches to the pharmacological treatment of Parkinson s disease. Peter Jenner King s College UK

Novel approaches to the pharmacological treatment of Parkinson s disease. Peter Jenner King s College UK Novel approaches to the pharmacological treatment of Parkinson s disease Peter Jenner King s College UK Disclosures and Disclaimers Speakers fees and consultancy fees have been received from Britannia

More information

Treatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS

Treatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS Treatment of Parkinson s Disease and of Spasticity Satpal Singh Pharmacology and Toxicology 3223 JSMBS singhs@buffalo.edu 716-829-2453 1 Disclosures NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS

More information

Parkinson s Disease Current Treatment Options

Parkinson s Disease Current Treatment Options Parkinson s Disease Current Treatment Options Daniel Kassicieh, D.O., FAAN Sarasota Neurology, P.A. PD: A Chronic Neurodegenerative Ds. 1 Million in USA Epidemiology 50,000 New Cases per Year Majority

More information

Movement Disorders: A Brief Overview

Movement Disorders: A Brief Overview Movement Disorders: A Brief Overview Albert Hung, MD, PhD Massachusetts General Hospital Harvard Medical School August 17, 2006 Cardinal Features of Parkinsonism Tremor Rigidity Bradykinesia Postural imbalance

More information

Continuous dopaminergic stimulation

Continuous dopaminergic stimulation Continuous dopaminergic stimulation Angelo Antonini Milan, Italy GPSRC CNS 172 173 0709 RTG 1 As PD progresses patient mobility becomes increasingly dependent on bioavailability of peripheral levodopa

More information

parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to

parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to crystallization of the drug, which caused unreliable drug

More information

Parkinson s Disease in the Elderly A Physicians perspective. Dr John Coyle

Parkinson s Disease in the Elderly A Physicians perspective. Dr John Coyle Parkinson s Disease in the Elderly A Physicians perspective Dr John Coyle Overview Introduction Epidemiology and aetiology Pathogenesis Diagnosis and clinical features Treatment Psychological issues/ non

More information

Parkinson s Disease Medications: Professionals Edition

Parkinson s Disease Medications: Professionals Edition Parkinson s Disease Clinic and Research Center University of California, San Francisco 505 Parnassus Ave., Rm. 795-M, Box 0114 San Francisco, CA 94143-0114 (415) 476-9276 http://pdcenter.neurology.ucsf.edu

More information

Parkinson s National Audit 2015

Parkinson s National Audit 2015 + Parkinson s National Audit 2015 Audit team Dr Dipen Gandecha, Specialty Doctor Claire Andrew, Parkinson s Disease Practitioner Dr William Wareing, Registrar Victoria Peers, Clinical Audit Officer Project

More information

WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019

WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019 WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019 YOUNG ONSET PARKINSON S DISEASE Definition: Parkinson s disease diagnosed

More information

History Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson

History Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson Parkinsonismm History Parkinson`s disease Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson Definition : Parkinsonism: Parkinsonism is a progressive neurological

More information

Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits

Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits Overview Overview Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits The differential diagnosis of Parkinson s disease Primary vs. Secondary Parkinsonism Proteinopathies:

More information

Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.

Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O. Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O. Parkinson s Epidemiology AFFECTS 1% OF POPULATION OVER 65 MEAN AGE OF ONSET 65 MEN:WOMEN 1.5:1 IDIOPATHIC:HEREDITARY 90:10

More information

Parkinson s Disease: initial diagnosis, initial treatment & non-motor features. J. Timothy Greenamyre, MD, PhD

Parkinson s Disease: initial diagnosis, initial treatment & non-motor features. J. Timothy Greenamyre, MD, PhD Parkinson s Disease: initial diagnosis, initial treatment & non-motor features J. Timothy Greenamyre, MD, PhD Involuntary tremulous motion, with lessened muscular power, in parts not in action and even

More information

Drug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Drug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Drug Therapy of Parkinsonism Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Parkinsonism is a progressive neurological disorder of muscle movement, usually

More information

Parkinson s disease and primary care

Parkinson s disease and primary care Neurology 427 Parkinson s disease and primary care The publication of the 2006 NICE guidelines for Parkinson s disease may seem to have taken much of the management of patients with Parkinson s disease

More information

PD: Key Treatment Considerations

PD: Key Treatment Considerations PD: Key Treatment Considerations 2018 Management of Neurologic and Neurosurgical Disorders in Daily Practice Elise Anderson MD Medical Co-Director, PBSI Movement Disorders 11/27/2018 1 Outline Treatment

More information

Dorset Medicines Advisory Group SHARED CARE GUIDELINES FOR PRESCRIBING ENTACAPONE (INCLUDING IN COMBINATION) OR OPICAPONE IN PARKINSON S DISEASE

Dorset Medicines Advisory Group SHARED CARE GUIDELINES FOR PRESCRIBING ENTACAPONE (INCLUDING IN COMBINATION) OR OPICAPONE IN PARKINSON S DISEASE SHARED CARE GUIDELINES FOR PRESCRIBING ENTACAPONE (INCLUDING IN COMBINATION) OR OPICAPONE IN PARKINSON S DISEASE INDICATION By inhibiting metabolism of levodopa, entacapone or opicapone allow a reduction

More information

05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century

05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century Peter Silburn Professor Clinical Neuroscience University of Queensland Queensland Brain Institute Neurosciences Queensland Impact of in Australia Second most common neurodegenerative disorder Up to 64,000

More information

Update on Parkinson s disease and other Movement Disorders October 2018

Update on Parkinson s disease and other Movement Disorders October 2018 Update on Parkinson s disease and other Movement Disorders October 2018 DR. JONATHAN EVANS CONSULTANT IN NEUROLOGY QUEEN S MEDICAL CENTRE NOTTINGHAM Disclosures: Honoraria UCB, Britannia, Allergan, AbbVie

More information

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that

More information

2015 UK Parkinson s Audit Patient and carer report

2015 UK Parkinson s Audit Patient and carer report 2015 UK Parkinson s Audit Patient and carer report Introduction This is a summary of the main findings of the 2015 UK Parkinson s Audit. This is the fifth and largest audit of Parkinson s to date. This

More information

DIFFERENTIAL DIAGNOSIS SARAH MARRINAN

DIFFERENTIAL DIAGNOSIS SARAH MARRINAN Parkinson s Academy Registrar Masterclass Sheffield DIFFERENTIAL DIAGNOSIS SARAH MARRINAN 17 th September 2014 Objectives Importance of age in diagnosis Diagnostic challenges Brain Bank criteria Differential

More information

What s new for diagnosing and treating Parkinson s Disease?

What s new for diagnosing and treating Parkinson s Disease? What s new for diagnosing and treating Parkinson s Disease? Erika Driver-Dunckley, MD Associate Professor of Neurology Program Director Movement Disorders Fellowship Assistant Program Director Neurology

More information

Psychiatric aspects of Parkinson s disease an update

Psychiatric aspects of Parkinson s disease an update Psychiatric aspects of Parkinson s disease an update Dr Chris Collins 027 2787593 chris.collins@cdhb.health.nz Disclosures: none Non-motor aspects physical Sensory anosmia, visual symptoms Speech and

More information

Welcome and Introductions

Welcome and Introductions Parkinson s Disease Spotlight on Addressing Motor and Non-Motor Symptoms The Changing Landscape Wednesday, March 8, 2017 Welcome and Introductions Stephanie Paul Vice President Development and Marketing

More information

Parkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s

Parkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s Parkinson s Disease Update Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s What is a movement disorder? Neurological disorders that affect ability to move by causing

More information

TRANSPARENCY COMMITTEE OPINION. 18 March 2009

TRANSPARENCY COMMITTEE OPINION. 18 March 2009 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 March 2009 REQUIP LP 2 mg extended-release tablet Box of 21 tablets (CIP: 379 214-8) Box of 28 tablets (CIP: 379

More information

NICE guideline Published: 19 July 2017 nice.org.uk/guidance/ng71

NICE guideline Published: 19 July 2017 nice.org.uk/guidance/ng71 Parkinson s disease in adults NICE guideline Published: 19 July 2017 nice.org.uk/guidance/ng71 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).

More information

Subthalamic Nucleus Deep Brain Stimulation (STN-DBS)

Subthalamic Nucleus Deep Brain Stimulation (STN-DBS) Subthalamic Nucleus Deep Brain Stimulation (STN-DBS) A Neurosurgical Treatment for Parkinson s Disease Parkinson s Disease Parkinson s disease is a common neurodegenerative disorder that affects about

More information

MANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE WHO ARE NIL BY MOUTH OR WITH A COMPROMISED SWALLOW

MANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE WHO ARE NIL BY MOUTH OR WITH A COMPROMISED SWALLOW MANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE WHO ARE NIL BY MOUTH OR WITH A COMPROMISED SWALLOW Author: Gordon W Duncan Status: Approved Authorised by: Clinical Policy Group Version: 1.0 Review date:

More information

Parkinson s Disease. Sirilak yimcharoen

Parkinson s Disease. Sirilak yimcharoen Parkinson s Disease Sirilak yimcharoen EPIDEMIOLOGY ~1% of people over 55 years Age range 35 85 years peak age of onset is in the early 60s ~5% of cases characterized by an earlier age of onset (typically

More information

Faculty. Joseph Friedman, MD

Faculty. Joseph Friedman, MD Faculty Claire Henchcliffe, MD, DPhil Associate Professor of Neurology Weill Cornell Medical College Associate Attending Neurologist New York-Presbyterian Hospital Director of the Parkinson s Institute

More information

Pharmacological treatment of Parkinson's disease

Pharmacological treatment of Parkinson's disease Pharmacological treatment of Parkinson's disease Joaquim Ferreira, MD, PhD Laboratory of Clinical Pharmacology and Therapeutics Faculty of Medicine University of Lisbon PD PROGRESSION DISABILITY instability

More information

Motor Fluctuations in Parkinson s Disease

Motor Fluctuations in Parkinson s Disease Motor Fluctuations in Parkinson s Disease Saeed Bohlega, MD, FRCPC Senior Distinguished Consultant Department of Neurosciences King Faisal Specialist Hospital & Research Centre Outline Type of fluctuations

More information

PD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N.

PD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N. PD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N. To hear the session live on: Tuesday, April 17, 2012 at 1:00 PM ET. DIAL: 1 (888) 272-8710 and

More information

2/20/18. History of Parkinson s. What is happening in the brain? DOPAMINE! Epidemiology. Parkinson s Disease. It s much more than tremor

2/20/18. History of Parkinson s. What is happening in the brain? DOPAMINE! Epidemiology. Parkinson s Disease. It s much more than tremor Parkinson s Disease History of Parkinson s It s much more than tremor Laura Dixon, DNP, MPA, APRN, FNP-BC University of Louisville Department of Neurology Movement Disorders Division Parkinson s Disease

More information

Welcome and Introductions

Welcome and Introductions Parkinson s Disease Spotlight on Treatment Advances Tuesday, January 26, 2016 Welcome and Introductions Stephanie Paul Vice President Development and Marketing American Parkinson Disease Association 1

More information

PARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada

PARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada PARKINSON S PRIMER Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada COPYRIGHT 2017 BY SEA COURSES INC. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted

More information

Moving fast or moving slow: an overview of Movement Disorders

Moving fast or moving slow: an overview of Movement Disorders Moving fast or moving slow: an overview of Movement Disorders Mini Medical School October 25, 2018 Heather Rigby, MD, FRCPC 2014 MFMER slide-1 2014 MFMER slide-2 Basal Ganglia Dysfunction - Movement Disorders

More information

Guidelines for acute treatment of patients with Parkinson s disease including those who are nil by mouth

Guidelines for acute treatment of patients with Parkinson s disease including those who are nil by mouth Index No: MMG48 Guidelines for acute treatment of patients with Parkinson s disease including those who are nil by mouth Version: 2.0 Date ratified: November 2017 Ratified by: (Name of Committee) Name

More information

THE ART OF MEDICATION MANAGEMENT IN PARKINSON S DISEASE

THE ART OF MEDICATION MANAGEMENT IN PARKINSON S DISEASE THE ART OF MEDICATION MANAGEMENT IN PARKINSON S DISEASE J O N AT H A N S Q U I R E S, M D, F R C P C C L I N I C A L I N S T R U C T O R, UBC F AC U L T Y O F M E D I C I N E P AC I F I C P AR K I N S

More information

Medicines Management and the Unwell Parkinson s Patient

Medicines Management and the Unwell Parkinson s Patient Medicines Management and the Unwell Parkinson s Patient Belinda Kessel Geriatrician and Movement Disorder Specialist Princess Royal University Hospital Orpington, Kent The Society for Acute Medicine, 7

More information

Elements for a public summary

Elements for a public summary VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology Parkinson s disease affects individuals globally (WHO 2006). It is the most common serious movement disorder, including speech

More information

8/28/2017. Behind the Scenes of Parkinson s Disease

8/28/2017. Behind the Scenes of Parkinson s Disease BEHIND THE SCENCES IN Parkinson s Disease Behind the Scenes of Parkinson s Disease Anna Marie Wellins DNP, ANP C Objectives Describe prevalence of Parkinson's disease (PD) Describe the hallmark pathologic

More information

Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University

Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University I have no financial interest with any entity producing marketing, re-selling,

More information

Parkinson s for Care Staff

Parkinson s for Care Staff Unit 28: Understand Parkinson s for Care Staff Unit reference number: A/616/7339 Level: 3 Unit type: Optional Credit value: 2 Guided learning hours: 14 Unit summary Parkinson s is a progressive neurological

More information

Shared Care Guideline

Shared Care Guideline Shared Care Guideline Rotigotine Executive Summary Indication: Parkinson s disease, either alone or as an adjunct to co-beneldopa or co-careldopa. Patient Group: Patients with early-stage idiopathic Parkinson

More information

Anticholinergics. COMT* Inhibitors. Dopaminergic Agents. Dopamine Agonists. Combination Product

Anticholinergics. COMT* Inhibitors. Dopaminergic Agents. Dopamine Agonists. Combination Product Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Class Update: Parkinson s Drugs Month/Year of Review:

More information

CLINICAL GUIDELINE FOR THE MANAGEMENT OF INPATIENTS WITH PARKINSON S DISEASE

CLINICAL GUIDELINE FOR THE MANAGEMENT OF INPATIENTS WITH PARKINSON S DISEASE CLINICAL GUIDELINE FOR THE MANAGEMENT OF INPATIENTS WITH PARKINSON S DISEASE 1. Aim/Purpose of this Guideline To assist all doctors and nurses in the care of inpatients with Parkinson s disease. This guideline

More information

Prior Authorization with Quantity Limit Program Summary

Prior Authorization with Quantity Limit Program Summary Gocovri (amantadine) Prior Authorization with Quantity Limit Program Summary This prior authorization applies to Commercial, NetResults A series, SourceRx and Health Insurance Marketplace formularies.

More information

ASSFN Clinical Case: Bilateral STN DBS Implant for Parkinson s Disease

ASSFN Clinical Case: Bilateral STN DBS Implant for Parkinson s Disease ASSFN Clinical Case: Bilateral STN DBS Implant for Parkinson s Disease Parkinson s Disease Cardinal Signs: Resting tremor Rigidity Bradykinesia Postural instability Other Symptoms Dystonia Dysphagia Autonomic

More information

Ratified by: Care and Clinical Policies Date: 17 th February 2016

Ratified by: Care and Clinical Policies Date: 17 th February 2016 Clinical Guideline Reference Number: 0803 Version 5 Title: Physiotherapy guidelines for the Management of People with Multiple Sclerosis Document Author: Henrieke Dimmendaal / Laura Shenton Date February

More information

Parkinson s Disease in 60 minutes. Dr. Claire Hinnell Movement Disorder Neurologist Director Movement Disorder Clinic JPOCSC

Parkinson s Disease in 60 minutes. Dr. Claire Hinnell Movement Disorder Neurologist Director Movement Disorder Clinic JPOCSC Parkinson s Disease in 60 minutes Dr. Claire Hinnell Movement Disorder Neurologist Director Movement Disorder Clinic JPOCSC S Plan of attack S What causes Parkinson s disease brief S Symptoms/Diagnostic

More information

SHARED CARE PRESCRIBING GUIDELINE

SHARED CARE PRESCRIBING GUIDELINE WORKING IN PARTNERSHIP WITH Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath) North East Hampshire & Farnham CCG, Crawley CCG, Horsham & Mid-Sussex

More information

Alison Charleston 1 st September 2016

Alison Charleston 1 st September 2016 Alison Charleston 1 st September 2016 Clinical features of Parkinson s disease Differential diagnosis Management of the motor features Non-motor and neuropsychiatric aspects 100-200 per 100,000 prevalence

More information

Parkinson s Disease medications

Parkinson s Disease medications Parkinson s Disease medications In correlation to the Unified Parkinson s disease rating scale Ayaan Mohamed Degree Thesis in Pharmacy 15 ECTS Bachelor s Level Report passed: Spring 2017 Supervisor: Miles

More information

Parkinson s Disease. Patients will ask you. 8/14/2015. Objectives

Parkinson s Disease. Patients will ask you. 8/14/2015. Objectives Parkinson s Disease Jean Van Kingsley MS, FNP-BC Objectives Describe the pathophysiolgy of PD. Review clinical charachteristics of PD. Identify management strategies, to maximize functional status. Recognize

More information

Margo J Nell Dept Pharmacology

Margo J Nell Dept Pharmacology Margo J Nell Dept Pharmacology 1 The extra pyramidal system Separation of cortico-spinal system (pyramidal system, (PS)) from the basal ganglia (extra pyramidal motor system (EPS)) because they produce

More information

Appendix 2: Admissions checklists for people with Parkinson s

Appendix 2: Admissions checklists for people with Parkinson s Appendix 2: Admissions checklists for people with Parkinson s This document is intended to form the basis of a locally developed tool and so it has been built to be amended with relevant local information,

More information

Understanding Parkinson s Disease Important information for you and your loved ones

Understanding Parkinson s Disease Important information for you and your loved ones Patient Education Understanding Parkinson s Disease Important information for you and your loved ones This handout explains the signs, symptoms, and possible treatments of Parkinson s disease. Parkinson

More information

2-The age at onset of PD is variable, usually between 50 and 80 years, with a mean onset of 55 years (1).

2-The age at onset of PD is variable, usually between 50 and 80 years, with a mean onset of 55 years (1). Parkinson Disease 1-Parkinson disease (PD) is a chronic, progressive movement disorder resulting from loss of dopamine from the nigrostriatal tracts in the brain, and is characterized by rigidity, bradykinesia,

More information

Cardinal Features of Parkinson s. Management of Parkinson s Disease. Drug Induced Parkinson s. Other Parkinson s Symptoms.

Cardinal Features of Parkinson s. Management of Parkinson s Disease. Drug Induced Parkinson s. Other Parkinson s Symptoms. Cardinal Features of Parkinson s Management of Parkinson s Disease Kristin S. Meyer, PharmD, CGP, FASHP Assistant Professor of Pharmacy Practice Drake University & Iowa Veterans Home Spring 2009 Tremor

More information

475 GERIATRIC PSYCHOPHARMACOLOGY (p.1)

475 GERIATRIC PSYCHOPHARMACOLOGY (p.1) 475 GERIATRIC PSYCHOPHARMACOLOGY (p.1) I. General Information? Use lower doses? Start low and go slow? Expect prolonged elimination ½ lives? Expect sedative-hypnotics to be dementing, to impair cognitive

More information